Home LiteratureArticle Details
PMID: 7491698 Published · ppublish English Comparative Study Journal Article

Elevated inflammatory cytokine levels in bone marrow graft rejection.

Transplantation ·Vol. 60 ·No. 9 ·1995-11-15 ·Pages 943-8

Nagler A, Or R, Nisman B, Kalickman I, Slavin S, Barak V

Abstract

Graft rejection and graft failure represent major obstacles in allogeneic bone marrow transplantation (BMT). Cytokines possibly play a central role in the inflammatory and allospecific components of allograft rejection. Therefore, we evaluated inflammatory cytokine levels following BMT in 12 consecutive patients with graft rejection (GR). Seven of the patients underwent BMT from siblings (6 matched and 1 mismatched), 4 patients received bone marrow from other family members (3 mismatched and 1 matched), and 1 patient underwent HLA-matched unrelated BMT. Nine of 12 had a sex-mismatched BMT and 5/12 had an ABO-mismatched BMT. Nine of 12 underwent T cell-depleted (Campath anti-CDw52 moAb) BMT. Rejection was defined as marrow hypoplasia with a peripheral white blood cell count < 0.5 x 10(9)/L 21 days after BMT, in conjunction with the absence of donor cells by polymerase chain reaction analysis using a sex-mismatched probe and/or a tumor-specific probe (BCR/ABL). Twenty-five patients who underwent uneventful BMT with no GR served as controls. The levels of tumor necrosis factor (TNF), interleukin-6 (IL-6), and interleukin-1 (IL-1) were evaluated by a high sensitive RIA or an enzyme immunoassay. The levels of TNF and IL-6 were found to be higher in 10/12 and 7/7 evaluated GR patients, respectively, as compared with controls (P < 0.05). The level of IL-1 was high only in 2/12 patients. TNF elevation occurred in all patients immediately after GR. TNF and IL-6 levels were significantly higher for patients with early rejection (< 35 days after BMT) as compared with patients with late rejection (> 35 days after BMT) (P < 0.049 and P < 0.006, respectively). Eight patients engrafted after the second transplant (2 only transient). All 6 patients with stable engraftment are alive (4 with basic disease), while the 4 patients who did not engraft and the 2 patients with only transient engraftment died. In the 6 patients with no engraftment or only transient engraftment, the elevated TNF levels remained high; in the 6 patients who had stable engraftment after retransplant, TNF levels, but not IL-6 levels, decreased. In conclusion, a majority of the patients with GR displayed high levels of inflammatory cytokines (TNF and IL-6). Dysregulation of inflammatory cytokines may be involved in the pathogenesis of GR.

MeSH Terms
ABO Blood-Group System Adolescent Adult Blood Group Incompatibility Bone Marrow Transplantation/immunology Child Cytokines/blood Female Follow-Up Studies Graft Rejection/blood,immunology,therapy Granulocyte-Macrophage Colony-Stimulating Factor/therapeutic use Histocompatibility Testing Humans Interleukin-1/blood Interleukin-3/therapeutic use Interleukin-6/blood Lymphocyte Depletion Male Middle Aged Reference Values T-Lymphocytes Time Factors Tissue Donors Tumor Necrosis Factor-alpha/analysis Whole-Body Irradiation
Chemicals
ABO Blood-Group System Cytokines Interleukin-1 Interleukin-3 Interleukin-6 Tumor Necrosis Factor-alpha Granulocyte-Macrophage Colony-Stimulating Factor
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Nagler A
Department of Bone Marrow Transplantation, Hadassah University Hospital, Jerusalem, Israel.
Or R
Nisman B
Kalickman I
Slavin S
Barak V
Article Info
Journal
Transplantation
Abbr.
Transplantation
ISSN
0041-1337
Published
1995-11-15
Pages
943-8
Language
English
Region
United States
NLM ID
0132144
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]